Abstract
Chronic lymphocytic leukaemia (CLL) is the most common leukaemia among the adults in the Western World. CLL (and the corresponding nodal entity small lymphocytic lymphoma, SLL) is classified as a lymphoproliferative disorder characterised by the relentless accumulation of mature B-lymphocytes showing a peculiar immunophenotype in the peripheral blood, bone marrow, lymph nodes and spleen. CLL clinical course is very heterogeneous: the majority of patients follow an indolent clinical course with no or delayed treatment need and with a prolonged survival, while others experience aggressive disease requiring early treatment followed by frequent relapses. In the last decade, the improved understanding of CLL pathogenesis shed light on premalignant conditions (i.e., monoclonal B-cell lymphocytosis, MBL), defined new prognostic and predictive markers, improving patient stratification, but also broadened the therapeutic armamentarium with novel agents, targeting fundamental signaling pathways.
| Original language | English |
|---|---|
| Journal | Critical Reviews in Oncology/Hematology |
| DOIs | |
| Publication status | Accepted/In press - Feb 10 2015 |
Fingerprint
Keywords
- Chronic lymphocytic leukaemia
- Leukaemias
- Lymphoproliferative disorders
ASJC Scopus subject areas
- Oncology
- Hematology
- Geriatrics and Gerontology
Cite this
Chronic lymphocytic leukaemia. / Scarfò, Lydia; Ferreri, Andrés J M; Ghia, Paolo.
In: Critical Reviews in Oncology/Hematology, 10.02.2015.Research output: Contribution to journal › Article
}
TY - JOUR
T1 - Chronic lymphocytic leukaemia
AU - Scarfò, Lydia
AU - Ferreri, Andrés J M
AU - Ghia, Paolo
PY - 2015/2/10
Y1 - 2015/2/10
N2 - Chronic lymphocytic leukaemia (CLL) is the most common leukaemia among the adults in the Western World. CLL (and the corresponding nodal entity small lymphocytic lymphoma, SLL) is classified as a lymphoproliferative disorder characterised by the relentless accumulation of mature B-lymphocytes showing a peculiar immunophenotype in the peripheral blood, bone marrow, lymph nodes and spleen. CLL clinical course is very heterogeneous: the majority of patients follow an indolent clinical course with no or delayed treatment need and with a prolonged survival, while others experience aggressive disease requiring early treatment followed by frequent relapses. In the last decade, the improved understanding of CLL pathogenesis shed light on premalignant conditions (i.e., monoclonal B-cell lymphocytosis, MBL), defined new prognostic and predictive markers, improving patient stratification, but also broadened the therapeutic armamentarium with novel agents, targeting fundamental signaling pathways.
AB - Chronic lymphocytic leukaemia (CLL) is the most common leukaemia among the adults in the Western World. CLL (and the corresponding nodal entity small lymphocytic lymphoma, SLL) is classified as a lymphoproliferative disorder characterised by the relentless accumulation of mature B-lymphocytes showing a peculiar immunophenotype in the peripheral blood, bone marrow, lymph nodes and spleen. CLL clinical course is very heterogeneous: the majority of patients follow an indolent clinical course with no or delayed treatment need and with a prolonged survival, while others experience aggressive disease requiring early treatment followed by frequent relapses. In the last decade, the improved understanding of CLL pathogenesis shed light on premalignant conditions (i.e., monoclonal B-cell lymphocytosis, MBL), defined new prognostic and predictive markers, improving patient stratification, but also broadened the therapeutic armamentarium with novel agents, targeting fundamental signaling pathways.
KW - Chronic lymphocytic leukaemia
KW - Leukaemias
KW - Lymphoproliferative disorders
UR - http://www.scopus.com/inward/record.url?scp=84979659027&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=84979659027&partnerID=8YFLogxK
U2 - 10.1016/j.critrevonc.2016.06.003
DO - 10.1016/j.critrevonc.2016.06.003
M3 - Article
AN - SCOPUS:84979659027
JO - Critical Reviews in Oncology/Hematology
JF - Critical Reviews in Oncology/Hematology
SN - 1040-8428
ER -